Patents Examined by Eric Olson
  • Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
    Patent number: 11035850
    Abstract: This application provides methods to quantitate drug incorporation into DNA and of simultaneously measuring DNA methylation levels. Drugs include nucleoside analog DNA methyltransferase inhibitors.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: June 15, 2021
    Assignee: The Johns Hopkins University
    Inventors: Michelle A. Rudek-Renaut, Srinivasan Yegnasubramanian, Nicole Anders
  • Low-dose triple combination formulation
    Patent number: 11033544
    Abstract: Provided herein are pharmaceutical compositions that are useful for the treatment of diabetes and associated conditions, diseases, and disorders.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: June 15, 2021
    Assignee: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
    Inventors: Stephen MacMahon, Anthony Rodgers
  • Treatment for improving the use of dietary sugar for energy purposes
    Patent number: 11032021
    Abstract: The invention relates to the use of a very low dosage form of abscisic acid (ABA) or an in vivo hydrolysable conjugate thereof, preferably ABA-glucosyl ester (ABA-GE), for nutracentic/therapeutic use for controlling and/or preventing hyperglycaemia and weight gain in response to sugar intake with a reduction in insulin secret and an increase in muscle performance.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 8, 2021
    Assignee: NUTRAVIS S.R.L.
    Inventors: Elena Zocchi, Mirko Magnone, Umberto Benatti, Giovanni Del Re, Antonio De Flora
  • Topical use of levofloxacin for reducing lung inflammation
    Patent number: 11020481
    Abstract: The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 1, 2021
    Assignee: Horizon Orphan LLC
    Inventors: Michael N. Dudley, Ruslan Y. Tsivkovski, David C. Griffith, Olga Rodny
  • Synergistic compositions of bioactive agents for optimizing cellular health
    Patent number: 11013710
    Abstract: The present invention discloses herein a synergistic composition(s) of bioactive agents for optimizing cellular health. Particularly, a synergistic bioactive composition for optimizing cellular health, wherein the composition comprising therapeutic blend of betaine of thiol histidine and sirtuin activator(s) or salts thereof present in the ratio of 1:0.5 to 1:90, along with pharmaceutically acceptable excipients. In another embodiment, the invention discloses novel synergistic nutritional composition comprising synergistic combination of bioactives L-ergothioneine and nicotinamide mononucleotide chloride present in the ratio ranges from 1:1 to 1:80. The present invention provides promising and effective nutritional composition for improving cellular health by regulating expression of transcriptional factor, pro-inflammatory cytokines, and reducing cell apoptosis, ROS level and DNA damage in the cell.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: May 25, 2021
    Assignee: CELAGENEX RESEARCH (INDIA) PVT. LTD.
    Inventors: Dhiraj Dhamane, Rajendra Prasad Tongra
  • Reversibly blocked nucleoside analogues and their use
    Patent number: 10988501
    Abstract: Reversibly blocked nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 27, 2021
    Inventors: Handong Li, Snezana Drmanac, Radoje Drmanac, Xun Xu, Lingling Peng, Scott Gablenz
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 10981942
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 20, 2021
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • Anti-fungal compounds
    Patent number: 10980754
    Abstract: The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: April 20, 2021
    Assignees: SAINT LOUIS UNIVERSITY, RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Maureen J. Donlin, John Edwin Tavis, Ryan Murelli, Marvin J. Meyers
  • Modified biopolymers and methods of producing and using the same
    Patent number: 10982013
    Abstract: Modified biopolymers, such as, charge-modified biopolymers, cross-linked biopolymers, and cross-linked, charge-modified biopolymers are provided along with methods of producing and using the same.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: April 20, 2021
    Inventors: Ali Ayoub, James Charles Bray, Ryan Nicholas Chan
  • Boron-containing compound
    Patent number: 10975104
    Abstract: To provide a novel boron-containing compound. A compound represented by the following formula: wherein black circle represents B, white circles represent B—H; —R1 represents —(CH2)n-X1—R3 (n represents an integer of 0 to 6; X1 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; R3 represents C6-C20 alkyl, hydroxy C6-C20 alkyl, amino C6-C20 alkyl, azido C6-C20 alkyl, hydroxycarbonyl C6-C20 alkyl, or the like), or a group having a repeating sequence of —(CH2)2—O— 3 times or more and 10 times or less and having a methyl group or an ethyl group at the end on the oxygen atom side; and —R2 is —(CH2)m-X2—R4 (m represents an integer from 0 to 8; X2 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; and R4 represents a tumor recognition moiety), or does not exist are prepared and used.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: April 13, 2021
    Assignees: STELLA PHARMA CORPORATION, OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION
    Inventors: Yoshihide Hattori, Kohki Uehara, Mitsunori Kirihata
  • IP and IP analogs dosage regimens for the treatment of ectopic calcifications
    Patent number: 10973838
    Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 13, 2021
    Assignee: SANIFIT THERAPEUTICS S.A.
    Inventors: Joan Perello Bestard, Carolina Salcedo Roca, Ana-Zeralda Canals Hamann
  • Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
    Patent number: 10973887
    Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 13, 2021
    Assignee: GENZYME CORPORATION
    Inventor: Yunxiang Zhu
  • Methods of treating heart failure with reduced ejection fraction
    Patent number: 10973836
    Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 13, 2021
    Assignee: ASTRAZENECA AB
    Inventor: Anna Maria Langkilde
  • Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
    Patent number: 10960078
    Abstract: The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: March 30, 2021
    Assignee: Shanghai Jiao Tong University
    Inventors: Deyue Yan, Ping Huang, Xinyuan Zhu, Wei Huang, Yongfeng Zhou
  • Chondroitin sulfate derivative and agent for treating bladder diseases
    Patent number: 10953037
    Abstract: A compound includes a group derived from chondroitin sulfate, a group derived from a steroid, and a spacer. The group derived from the chondroitin sulfate and the group derived from the steroid are covalently bonded together via the spacer, and a spacer forming molecule of the spacer is ?-alanine or isoleucine. A covalent bond between the group derived from the steroid and the spacer is an ester bond, and a covalent bond between the group derived from the chondroitin sulfate and the spacer is an amide bond. The steroid is at least one selected from the group consisting of prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide and fluticasone.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 23, 2021
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
  • Chemical structures for localized delivery of therapeutic agents
    Patent number: 10953098
    Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 23, 2021
    Assignees: The Regents of the University of California, Alchemical Research Holdings, LLC
    Inventors: Jose Manuel Mejia Oneto, Ziyad F. Al-Rashid
  • Method of disintegrating pulp for use in cellulose acetate production and method of producing cellulose acetate
    Patent number: 10954314
    Abstract: A method of disintegrating pulp for use in cellulose acetate production includes: a primary disintegration step of disintegrating a pulp sheet into pulp pieces having an average area of not more than 45 cm2; and a secondary disintegration step of disintegrating the pulp pieces with an impact shock exerted by a jet mill (20). The jet mill (20) includes: a cylindrical casing (21) provided with an inlet (21d) and an outlet (21e); and a rotor (25) including a plurality of blades (25a) provided on its outer peripheral portion, the plurality of blades (25a) facing an inner peripheral surface of the casing (21).
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 23, 2021
    Assignee: DAICEL CORPORATION
    Inventors: Mitsuteru Hosaka, Toshinori Okano, Yuji Ida
  • Mixtures of HMOs
    Patent number: 10946032
    Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 16, 2021
    Assignee: GLYCOM A/S
    Inventors: Elise Champion, Bruce McConnell, Gyula Dekany
  • Herpes zoster vaccine composition
    Patent number: 10940198
    Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 9, 2021
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Hyo Jung Nam, Eun Mi Kim, Duck Hyang Shin, Steven G. Reed, Kang Il Yoo, Sung Jun Hong
  • Rhamnolipid amides for hair scent retention
    Patent number: 10941173
    Abstract: The invention provides derivatives of rhamnolipids, formulations comprising these, and the use thereof.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 9, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Xin Lu, Sandra Nattland, Monica Desiree van Logchem, Hans Henning Wenk, Fabien Cabirol, Verena Dahl, Ralph Scheuermann, Kathrin Daniela Brandt, Jochen Kleinen